SCI
1. Purification and characterization of lipopolysaccharide induced TNF-like factor from rabbit serum. Immunol Lett. 1998; 60(2-3):97-102. IF=2.9
2. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells.J Biol Chem. 1998; 273(44):28805-12. IF=5.6
3. Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth. Biochem Biophys Res Commun. 1998;252(2):513-6. IF=2.7
4. N-acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity. J Biol Chem. 2001; 276(44):40591-8.. IF=5.6
5. Prothrombin kringle-2 activates cultured rat brain microglia. J Immunol. 2002;168(11):5805-10. IF=5.8
6. Recombinant human prothrombin kringles have potent anti-angiogenic activities and inhibit Lewis lung carcinoma tumor growth and metastases. Angiogenesis. 2002;5(3):191-201. IF=6.18
7. ADAM33 polymorphism: association with bronchial hyper-responsiveness in Korean asthmatics. Clin Exp Allergy. 2004;34(6):860-5. IF=4.195
8. Interleukin 3 (IL3) polymorphisms associated with decreased risk of asthma and atopy. J Hum Genet. 2004;49(10):517-27. IF=2.5
9. A single nucleotide polymorphism on the promoter of eotaxin1 associates with its mRNA expression and asthma phenotypes. J Immunol. 2005;174(3):1525-31. IF=5.8
10. Interferon-gamma inhibits in vitro mobilization of eosinophils by interleukin-5. Int Arch Allergy Immunol. 2005;136(3):295-302. IF=2.5
11. Association of eotaxin-2 gene polymorphisms with plasma eotaxin-2 concentration. J Hum Genet. 2005;50(3):118-23. IF=2.7
12. Titanium dioxide particle-induced goblet cell hyperplasia: association with mast cells and IL-13. Respir Res. 2005 13;6:34. IF=3.9
13. Interleukin-25 and interleukin-13 production by alveolar macrophages in response to particles. Am J Respir Cell Mol Biol. 2005;33(3):290-6. IF=4.3
14. Proteomic analysis of differently expressed proteins in a mouse model for allergic asthma. J Korean Med Sci. 2005;20(4):579-85. IF=1.0
15. Additive effect of diesel exhaust particulates and ozone on airway hyperresponsiveness and inflammation in a mouse model of asthma. J Korean Med Sci. 2005;20(5):759-63.IF=1.0
16. Complement C3a and C4a increased in plasma of patients with aspirin-induced asthma. Am J Respir Crit Care Med. 2006; 173(4):370-8. IF=10.7
17. A disintegrin and metalloproteinase 33 protein in patients with asthma: Relevance to airflow limitation. Am J Respir Crit Care Med. 2006 ; 173(7):729-35. IF=10.7
18. Proteomic identification of macrophage migration-inhibitory factor upon exposure to TiO2 particles. Mol Cell Proteomics. 2007; 6(1):56-63. IF=8.354
19. Association analysis of CD40 polymorphisms with asthma and the level of serum total IgE. Am J Respir Crit Care Med. 2007;175(8):775-82. IF=10.7
20. Effect and mechanism of lipopolysaccharide on allergen-induced interleukin-5 and eotaxins production by whole blood cultures of atopic asthmatics. Clin Exp Immunol. 2007;147(3):440-8. IF=4.195
21. Genetic effect of CCR3 and IL5RA gene polymorphisms on eosinophilia in asthmatic patients. J Allergy Clin Immunol. 2007;120(5):1110-7. IF=9.27
22. Ym1 and Ym2 expression in a mouse model exposed to diesel exhaust particles. Environ Toxicol. 2008;23(1):110-6. IF=2.0
23. The fast skeletal muscle myosin light chain is differentially expressed in smooth muscle cells of OVA-challenged mouse trachea. Mol Cells. 2008;25(1):78-85. IF=1.9
24. Asp-Tyr-Leu-Lys tetrapeptide inhibits airway inflammation in toluene-2,4-diisocyanate-induced asthma mice. Clin Exp Allergy. 2008;38(6):1025-32. IF=4.195
25. Association of angiotensin I-converting enzyme gene polymorphisms with aspirin intolerance in asthmatics. Clin Exp Allergy. 2008. 38(11):1727-37. IF=4.195
26. Isolation of cadmium-induced DNA sequence in microalga Nannochloropsis oculata. J Environ Biol. 2008; 29(4):457-60.IF=1.0
27. Plasma protein profiles in early asthmatic responses to inhalation allergen challenge. Allergy. 2009; 64(1):47-54. IF=6.38
28. Association of IL17RB Gene Polymorphism With Asthma. Chest. 2009 May;135(5):1173-1180. IF=6.519
29. Genetic effect of CysLTR2 polymorphisms on its mRNA synthesis and stabilization.BMC Med Genet. 2009 Oct 20; 10(1):106. IF=2.439
30. Role of Lung Apolipoprotein A1 in Idiopathic Pulmonary Fibrosis: Anti-inflammatory and Anti-fibrotic Effect on Experimental Lung Injury/Fibrosis. Am J Respir Crit Care Med. 22010 Sep 1;182(5):633-42. Epub 2010 May 12. IF=10.7
31. Vacuolar (H(+))-ATPases in Caenorhabditis elegans: What can we learn about giant H(+) pumps from tiny worms? Biochim Biophys Acta. 2010 Oct;1797(10):1687-1695. IF=4.0
32. Association of IKBA gene polymorphisms with the development of asthma. Hum Immunol. 2010 Nov;71(11):1147-53. Epub 2010 Jul 29. IF=2.7
33. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model. J Control Release. 2010 Nov 9. [Epub ahead of print] IF=7.164
34. Skin regeneration with fibroblast growth factor 2 released from heparin-conjugated fibrin. Biotechnol Lett. 2010 Dec 8. [Epub ahead of print] IF=1.6
35. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res. 2010 Dec 9. [Epub ahead of print] IF=5.46
36. Relationship between Group-specific Component Protein and the Development of Asthma. Am J Respir Crit Care Med. 2010 Dec 17. [Epub ahead of print] IF=10.7
37. Regulatory systems for hypoxia-inducible gene expression in ischemic heart disease gene therapy. Adv Drug Deliv Rev. 2011 Jan 15. [Epub ahead of print] IF: 13.57
38. Application of proteomics in asthma research. Expert Rev Proteomics. 2011 Apr;8(2):221-230. IF: 4.406
39.Combined delivery of dexamethasone and plasmid DNA in an animal model of LPS-induced acute lung injury. J Control Release. 2011 Jul 6. IF=7.164
40. Effect of Retinoic Acid on Epithelial Differentiation and Mucin Expression in Primary Human Corneal Limbal Epithelial Cells. Curr Eye Res. 2012;37(1):33-42 IF =2.025
41. CpG methylation at GATA elements in the regulatory region of CCR3 positively correlates with CCR3 transcription. Exp Mol Med. 2012; 44(4):268-80. IF=5.164
42. Fluorescently Labeled Nanoparticles Enable the Detection of Stem Cell-Derived Hepatocytes. Bull. Korean Chem. Soc. 2012; 33(6): 1983-1988. IF=0.793
43. T Cell-Specific siRNA Delivery Using Antibody-Conjugated Chitosan Nanoparticles. Bioconjug Chem. 2012; 23(6): 1174-1180. IF=4.5
44. Dexamethasone conjugation to polyamidoamine dendrimers G1 and G2 for enhanced transfection efficiency with an anti-inflammatory effect. J Drug Target. 2012; 20(8):667-77. IF=2.82
45. Preparation of biomimetic hydrogels with controlled cell adhesive properties and topographical features for the study of muscle cell adhesion and proliferation. Macromol Biosci. 2012;12(11):1502-13 IF=3.48
46. Preparation and characterization of nonaarginine-modified chitosan nanoparticles for siRNA delivery. Carbohydr Polym. 2013; 92(1):57-62. IF=4.074
47. Sequential delivery of TAT-HSP27 and VEGF using microsphere/hydrogel hybrid systems for therapeutic angiogenesis. J Control Release. 2013; 166(1):38-45. IF=7.633
46. Drug delivery systems for the treatment of ischemic stroke. Pharm Res. 2013; 30(10):2429-44. IF=3.26
47. Protective effects of protein transduction domain-metallothionein fusion proteins against hypoxia- and oxidative stress-induced apoptosis in an ischemia/reperfusion rat model. J Control Release. 2013;169(3):306-12. IF=7.633
48. Hypoxia as a target for tissue specific gene therapy. J Control Release. 2013; 172(2): 484-94 IF=7.633
49. Dexamethasone-conjugated polyethylenimine/MIF siRNA complex regulation of particulate matter-induced airway inflammation. Biomaterials. 2013; 34(30):7453-61. IF=8.387
50. Therapeutic use of stem cell transplantation for cell replacement or cytoprotective effect of microvesicle released from mesenchymal stem cell. Mol Cells. 2014;37(2):133-9. IF=2.67
51. Proteomic analysis in pterygium; upregulated protein expression of ALDH3A1, PDIA3, and PRDX2. Mol Vis. 2014 ;20:1192-202. IF=2.511
52. Conditioned medium of adipose-derived stromal cell culture in three-dimensional bioreactors for enhanced wound healing. J Surg Res. 2014: S0022-4804(14)00983-4.
53. The spacer arm length in cell-penetrating peptides influences chitosan/siRNA nanoparticle delivery for pulmonary inflammation treatment. Nanoscale. 2015 Dec 21;7(47):20095-104
54. Theranostic gas-generating nanoparticles for targeted ultrasound imaging and treatment of neuroblastoma. J Control Release. 2016;223:197-206 IF=7.633
55. Targeted delivery of growth factors in ischemic stroke animal models. Expert Opin Drug Deliv. 2016; 13(5):709-23 IF=4.84
56. Long-Term Effects of Diesel Exhaust Particles on Airway Inflammation and Remodeling in a Mouse Model. Allergy Asthma Immunol Res. 2016; 8(3):246-56.
57. Delivery of Hypoxia-Inducible Heme Oxygenase-1 Gene for Site-Specific Gene Therapy in the Ischemic Stroke Animal Model. Pharm Res. 2016; 33(9):2250-8 IF=3.26
58. Exosome and polymersome for potential theranostic applications Macromolecular Research 2016, 24,(7) 577-86
59. Combined delivery of temozolomide and the thymidine kinase gene for treatment of glioblastoma J Drug Target. 2016, 27:1-7. IF=2.821
60. Delivery of Hypoxia-Inducible Heme Oxygenase-1 Gene for Site-Specific Gene Therapy in the Ischemic Stroke Animal Model. Pharm Res. 2016;33(9):2250-8. IF=3.26
61. Targeted delivery of Chil3/Chil4 siRNA to alveolar macrophages using ternary complexes composed of HMG and oligoarginine micelles 2019, IF=7.233
2. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells.J Biol Chem. 1998; 273(44):28805-12. IF=5.6
3. Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth. Biochem Biophys Res Commun. 1998;252(2):513-6. IF=2.7
4. N-acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity. J Biol Chem. 2001; 276(44):40591-8.. IF=5.6
5. Prothrombin kringle-2 activates cultured rat brain microglia. J Immunol. 2002;168(11):5805-10. IF=5.8
6. Recombinant human prothrombin kringles have potent anti-angiogenic activities and inhibit Lewis lung carcinoma tumor growth and metastases. Angiogenesis. 2002;5(3):191-201. IF=6.18
7. ADAM33 polymorphism: association with bronchial hyper-responsiveness in Korean asthmatics. Clin Exp Allergy. 2004;34(6):860-5. IF=4.195
8. Interleukin 3 (IL3) polymorphisms associated with decreased risk of asthma and atopy. J Hum Genet. 2004;49(10):517-27. IF=2.5
9. A single nucleotide polymorphism on the promoter of eotaxin1 associates with its mRNA expression and asthma phenotypes. J Immunol. 2005;174(3):1525-31. IF=5.8
10. Interferon-gamma inhibits in vitro mobilization of eosinophils by interleukin-5. Int Arch Allergy Immunol. 2005;136(3):295-302. IF=2.5
11. Association of eotaxin-2 gene polymorphisms with plasma eotaxin-2 concentration. J Hum Genet. 2005;50(3):118-23. IF=2.7
12. Titanium dioxide particle-induced goblet cell hyperplasia: association with mast cells and IL-13. Respir Res. 2005 13;6:34. IF=3.9
13. Interleukin-25 and interleukin-13 production by alveolar macrophages in response to particles. Am J Respir Cell Mol Biol. 2005;33(3):290-6. IF=4.3
14. Proteomic analysis of differently expressed proteins in a mouse model for allergic asthma. J Korean Med Sci. 2005;20(4):579-85. IF=1.0
15. Additive effect of diesel exhaust particulates and ozone on airway hyperresponsiveness and inflammation in a mouse model of asthma. J Korean Med Sci. 2005;20(5):759-63.IF=1.0
16. Complement C3a and C4a increased in plasma of patients with aspirin-induced asthma. Am J Respir Crit Care Med. 2006; 173(4):370-8. IF=10.7
17. A disintegrin and metalloproteinase 33 protein in patients with asthma: Relevance to airflow limitation. Am J Respir Crit Care Med. 2006 ; 173(7):729-35. IF=10.7
18. Proteomic identification of macrophage migration-inhibitory factor upon exposure to TiO2 particles. Mol Cell Proteomics. 2007; 6(1):56-63. IF=8.354
19. Association analysis of CD40 polymorphisms with asthma and the level of serum total IgE. Am J Respir Crit Care Med. 2007;175(8):775-82. IF=10.7
20. Effect and mechanism of lipopolysaccharide on allergen-induced interleukin-5 and eotaxins production by whole blood cultures of atopic asthmatics. Clin Exp Immunol. 2007;147(3):440-8. IF=4.195
21. Genetic effect of CCR3 and IL5RA gene polymorphisms on eosinophilia in asthmatic patients. J Allergy Clin Immunol. 2007;120(5):1110-7. IF=9.27
22. Ym1 and Ym2 expression in a mouse model exposed to diesel exhaust particles. Environ Toxicol. 2008;23(1):110-6. IF=2.0
23. The fast skeletal muscle myosin light chain is differentially expressed in smooth muscle cells of OVA-challenged mouse trachea. Mol Cells. 2008;25(1):78-85. IF=1.9
24. Asp-Tyr-Leu-Lys tetrapeptide inhibits airway inflammation in toluene-2,4-diisocyanate-induced asthma mice. Clin Exp Allergy. 2008;38(6):1025-32. IF=4.195
25. Association of angiotensin I-converting enzyme gene polymorphisms with aspirin intolerance in asthmatics. Clin Exp Allergy. 2008. 38(11):1727-37. IF=4.195
26. Isolation of cadmium-induced DNA sequence in microalga Nannochloropsis oculata. J Environ Biol. 2008; 29(4):457-60.IF=1.0
27. Plasma protein profiles in early asthmatic responses to inhalation allergen challenge. Allergy. 2009; 64(1):47-54. IF=6.38
28. Association of IL17RB Gene Polymorphism With Asthma. Chest. 2009 May;135(5):1173-1180. IF=6.519
29. Genetic effect of CysLTR2 polymorphisms on its mRNA synthesis and stabilization.BMC Med Genet. 2009 Oct 20; 10(1):106. IF=2.439
30. Role of Lung Apolipoprotein A1 in Idiopathic Pulmonary Fibrosis: Anti-inflammatory and Anti-fibrotic Effect on Experimental Lung Injury/Fibrosis. Am J Respir Crit Care Med. 22010 Sep 1;182(5):633-42. Epub 2010 May 12. IF=10.7
31. Vacuolar (H(+))-ATPases in Caenorhabditis elegans: What can we learn about giant H(+) pumps from tiny worms? Biochim Biophys Acta. 2010 Oct;1797(10):1687-1695. IF=4.0
32. Association of IKBA gene polymorphisms with the development of asthma. Hum Immunol. 2010 Nov;71(11):1147-53. Epub 2010 Jul 29. IF=2.7
33. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model. J Control Release. 2010 Nov 9. [Epub ahead of print] IF=7.164
34. Skin regeneration with fibroblast growth factor 2 released from heparin-conjugated fibrin. Biotechnol Lett. 2010 Dec 8. [Epub ahead of print] IF=1.6
35. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res. 2010 Dec 9. [Epub ahead of print] IF=5.46
36. Relationship between Group-specific Component Protein and the Development of Asthma. Am J Respir Crit Care Med. 2010 Dec 17. [Epub ahead of print] IF=10.7
37. Regulatory systems for hypoxia-inducible gene expression in ischemic heart disease gene therapy. Adv Drug Deliv Rev. 2011 Jan 15. [Epub ahead of print] IF: 13.57
38. Application of proteomics in asthma research. Expert Rev Proteomics. 2011 Apr;8(2):221-230. IF: 4.406
39.Combined delivery of dexamethasone and plasmid DNA in an animal model of LPS-induced acute lung injury. J Control Release. 2011 Jul 6. IF=7.164
40. Effect of Retinoic Acid on Epithelial Differentiation and Mucin Expression in Primary Human Corneal Limbal Epithelial Cells. Curr Eye Res. 2012;37(1):33-42 IF =2.025
41. CpG methylation at GATA elements in the regulatory region of CCR3 positively correlates with CCR3 transcription. Exp Mol Med. 2012; 44(4):268-80. IF=5.164
42. Fluorescently Labeled Nanoparticles Enable the Detection of Stem Cell-Derived Hepatocytes. Bull. Korean Chem. Soc. 2012; 33(6): 1983-1988. IF=0.793
43. T Cell-Specific siRNA Delivery Using Antibody-Conjugated Chitosan Nanoparticles. Bioconjug Chem. 2012; 23(6): 1174-1180. IF=4.5
44. Dexamethasone conjugation to polyamidoamine dendrimers G1 and G2 for enhanced transfection efficiency with an anti-inflammatory effect. J Drug Target. 2012; 20(8):667-77. IF=2.82
45. Preparation of biomimetic hydrogels with controlled cell adhesive properties and topographical features for the study of muscle cell adhesion and proliferation. Macromol Biosci. 2012;12(11):1502-13 IF=3.48
46. Preparation and characterization of nonaarginine-modified chitosan nanoparticles for siRNA delivery. Carbohydr Polym. 2013; 92(1):57-62. IF=4.074
47. Sequential delivery of TAT-HSP27 and VEGF using microsphere/hydrogel hybrid systems for therapeutic angiogenesis. J Control Release. 2013; 166(1):38-45. IF=7.633
46. Drug delivery systems for the treatment of ischemic stroke. Pharm Res. 2013; 30(10):2429-44. IF=3.26
47. Protective effects of protein transduction domain-metallothionein fusion proteins against hypoxia- and oxidative stress-induced apoptosis in an ischemia/reperfusion rat model. J Control Release. 2013;169(3):306-12. IF=7.633
48. Hypoxia as a target for tissue specific gene therapy. J Control Release. 2013; 172(2): 484-94 IF=7.633
49. Dexamethasone-conjugated polyethylenimine/MIF siRNA complex regulation of particulate matter-induced airway inflammation. Biomaterials. 2013; 34(30):7453-61. IF=8.387
50. Therapeutic use of stem cell transplantation for cell replacement or cytoprotective effect of microvesicle released from mesenchymal stem cell. Mol Cells. 2014;37(2):133-9. IF=2.67
51. Proteomic analysis in pterygium; upregulated protein expression of ALDH3A1, PDIA3, and PRDX2. Mol Vis. 2014 ;20:1192-202. IF=2.511
52. Conditioned medium of adipose-derived stromal cell culture in three-dimensional bioreactors for enhanced wound healing. J Surg Res. 2014: S0022-4804(14)00983-4.
53. The spacer arm length in cell-penetrating peptides influences chitosan/siRNA nanoparticle delivery for pulmonary inflammation treatment. Nanoscale. 2015 Dec 21;7(47):20095-104
54. Theranostic gas-generating nanoparticles for targeted ultrasound imaging and treatment of neuroblastoma. J Control Release. 2016;223:197-206 IF=7.633
55. Targeted delivery of growth factors in ischemic stroke animal models. Expert Opin Drug Deliv. 2016; 13(5):709-23 IF=4.84
56. Long-Term Effects of Diesel Exhaust Particles on Airway Inflammation and Remodeling in a Mouse Model. Allergy Asthma Immunol Res. 2016; 8(3):246-56.
57. Delivery of Hypoxia-Inducible Heme Oxygenase-1 Gene for Site-Specific Gene Therapy in the Ischemic Stroke Animal Model. Pharm Res. 2016; 33(9):2250-8 IF=3.26
58. Exosome and polymersome for potential theranostic applications Macromolecular Research 2016, 24,(7) 577-86
59. Combined delivery of temozolomide and the thymidine kinase gene for treatment of glioblastoma J Drug Target. 2016, 27:1-7. IF=2.821
60. Delivery of Hypoxia-Inducible Heme Oxygenase-1 Gene for Site-Specific Gene Therapy in the Ischemic Stroke Animal Model. Pharm Res. 2016;33(9):2250-8. IF=3.26
61. Targeted delivery of Chil3/Chil4 siRNA to alveolar macrophages using ternary complexes composed of HMG and oligoarginine micelles 2019, IF=7.233